Metformin, a drug prescribed for type 2 diabetes appears to starve cancer of breast cells by denying them access to the energetic nutrients. relationship between Metformin and breast cancer treatment studied for several years and has been tested in the laboratory with: drugs ADRIAMYCIN on breast cancer stem cells appears to increase the effectiveness of the treatment of breast cancer: drugs ADRIAMYCIN hormone sensitive, as well as positive and HER2-negative breast cancer three times.
A new study supported by Breakthrough Breast cancer have been aimed at the development of tests to determine which patients with breast cancer would benefit most from treatment with metformin. research was directed by Dr. Michael Lisanti Thomas Jefferson University and Dr. Anthony Howell Howell, University of Manchester. Dr. explained that "some cancer cells are fed by the healthy cells, we have an agent., which allows you to block that is Metforminawspólne of the medicines used to treat diabetes. "When asked how to help breast cancer patients, replied," "the potential benefit is that stops cancer cell powered by Normal cells and cancer cells will not grow."Dr. Howell also noted that Metformin is relatively inexpensive, particularly in comparison to standard drugs.
Women who are diagnosed with an aggressive form of breast cancer may be tested whether someday Metformin stops growth and recurrence of their cancer, if their tumor responds to drugs, then diabetes may take personalized treatment, based in particular on the nature of the tumor and the fuel required to grow Dr. Howell said, "this is a terrifically exciting. It is a step in the direction of having each patient get the right treatment for them-what is personalized medicine. We are looking for a new way to dispense the patient on the basis of which should correspond to the treatment we have, and which may be something else. "
Metformin is readily available and each pill costs around 10 pence in the United Kingdom or about 16 cents in the United States the results of the examination and Howell Lisanti was published in the journal cell cycle.
No comments:
Post a Comment